Annexon (ANNX) Stock Forecast, Price Target & Predictions
ANNX Stock Forecast
Annexon stock forecast is as follows: an average price target of $14.00 (represents a 94.44% upside from ANNX’s last price of $7.20) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
ANNX Price Target
The average price target for Annexon (ANNX) is $14.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $14.00 to $14.00. This represents a potential 94.44% upside from ANNX's last price of $7.20.
ANNX Analyst Ratings
According to 5 Wall Street analysts, Annexon's rating consensus is 'Buy'. The analyst rating breakdown for ANNX stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Annexon Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 05, 2024 | Derek Archila | Wells Fargo | $14.00 | $5.99 | 133.72% | 94.44% |
| May 15, 2024 | Derek Archila | Wells Fargo | $10.00 | $4.82 | 107.47% | 38.89% |
| Apr 01, 2024 | Derek Archila | Wells Fargo | $12.00 | $7.17 | 67.36% | 66.67% |
The latest Annexon stock forecast, released on Jun 05, 2024 by Derek Archila from Wells Fargo, set a price target of $14.00, which represents a 133.72% increase from the stock price at the time of the forecast ($5.99), and a 94.44% increase from ANNX last price ($7.20).
Annexon Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $12.00 |
| Last Closing Price | $7.20 | $7.20 | $7.20 |
| Upside/Downside | -100.00% | -100.00% | 66.67% |
In the current month, the average price target of Annexon stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Annexon's last price of $7.20. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 06, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jun 26, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jun 05, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| May 15, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Apr 01, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Dec 21, 2023 | Bank of America Securities | - | Buy | Upgrade |
| Sep 16, 2022 | Jefferies | - | Buy | Initialise |
| Nov 30, 2021 | H.C. Wainwright | - | Buy | Initialise |
Annexon's last stock rating was published by Cowen & Co. on Aug 06, 2024. The company gave ANNX a "Buy" rating, the same as its previous rate.
Annexon Financial Forecast
Annexon Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - | 4 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - |
Annexon's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ANNX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Annexon EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 4 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | $-29.18M |
| Avg Forecast | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - |
undefined analysts predict ANNX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Annexon's previous annual EBITDA (undefined) of $NaN.
Annexon Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 4 | 8 |
| Net Income | - | - | - | - | - | - | - | - | $-27.89M |
| Avg Forecast | $-37.74M | $-37.09M | $-35.79M | $-33.18M | $-36.34M | $-33.66M | $-29.86M | $-41.67M | $-34.07M |
| High Forecast | $-37.74M | $-37.09M | $-35.79M | $-33.18M | $-36.34M | $-28.48M | $-29.86M | $-41.67M | $-23.47M |
| Low Forecast | $-37.74M | $-37.09M | $-35.79M | $-33.18M | $-36.34M | $-40.14M | $-29.86M | $-41.67M | $-40.12M |
| Surprise % | - | - | - | - | - | - | - | - | 0.82% |
Annexon's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ANNX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Annexon SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 4 | 8 |
| SG&A | - | - | - | - | - | - | - | - | $5.91M |
| Avg Forecast | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - |
Annexon's average Quarter SG&A projection for Mar 24 is -, based on 4 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to ANNX last annual SG&A of $5.91M (Dec 23).
Annexon EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 4 | 8 |
| EPS | - | - | - | - | - | - | - | - | $-0.36 |
| Avg Forecast | $-0.29 | $-0.28 | $-0.28 | $-0.26 | $-0.28 | $-0.26 | $-0.23 | $-0.34 | $-0.44 |
| High Forecast | $-0.29 | $-0.28 | $-0.28 | $-0.26 | $-0.28 | $-0.22 | $-0.23 | $-0.34 | $-0.30 |
| Low Forecast | $-0.29 | $-0.28 | $-0.28 | $-0.26 | $-0.28 | $-0.31 | $-0.23 | $-0.34 | $-0.51 |
| Surprise % | - | - | - | - | - | - | - | - | 0.83% |
According to undefined Wall Street analysts, Annexon's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ANNX previous annual EPS of $NaN (undefined).
Annexon Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.74 | $70.00 | 9359.46% | Buy |
| INAB | IN8bio | $0.32 | $14.00 | 4275.00% | Buy |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| IMMX | Immix Biopharma | $1.86 | $7.00 | 276.34% | Buy |
| CNSP | CNS Pharmaceuticals | $0.15 | $0.50 | 233.33% | - |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| RLAY | Relay Therapeutics | $7.60 | $19.50 | 156.58% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| WVE | Wave Life Sciences | $5.86 | $14.00 | 138.91% | Buy |
| GPCR | Structure Therapeutics | $40.84 | $86.00 | 110.58% | Buy |
| RCUS | Arcus Biosciences | $17.95 | $35.20 | 96.10% | Buy |
| ANNX | Annexon | $7.20 | $14.00 | 94.44% | Buy |
| CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
| ZURA | Zura Bio | $3.70 | $5.00 | 35.14% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
ANNX Forecast FAQ
Is Annexon a good buy?
Yes, according to 5 Wall Street analysts, Annexon (ANNX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of ANNX's total ratings.
What is ANNX's price target?
Annexon (ANNX) average price target is $14 with a range of $14 to $14, implying a 94.44% from its last price of $7.2. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Annexon stock go up soon?
According to Wall Street analysts' prediction for ANNX stock, the company can go up by 94.44% (from the last price of $7.2 to the average price target of $14), up by 94.44% based on the highest stock price target, and up by 94.44% based on the lowest stock price target.
Can Annexon stock reach $11?
ANNX's average twelve months analyst stock price target of $14 supports the claim that Annexon can reach $11 in the near future.
What are Annexon's analysts' financial forecasts?
Annexon's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-142M (high $-136M, low $-148M), average SG&A $0 (high $0, low $0), and average EPS is $-1.107 (high $-1.067, low $-1.157). ANNX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-144M (high $-144M, low $-144M), average SG&A $0 (high $0, low $0), and average EPS is $-1.105 (high $-1.105, low $-1.105).